Exelixis Inc. (EXEL)

Oncology Corporate Profile

Stock Performance

24.7400
0.0100

3 Month Stock History Chart

HQ Location

210 East Grand Avenue
South San Francisco, CA 94080

Company Description

Exelixis is committed to making a meaningful impact on the lives of patients living with cancer. Exelixis is a development-stage biotechnology company with an uncommonly rich pipeline of twelve compounds in clinical development with many more advancing to the clinic.

Website: http://www.exelixis.com

Brand Generic Indication
Cabometyx®cabozantinibCabometyx® is a kinase inhibitor indicated for the treatment of patients with advanced renal cell carcinoma (RCC) who have received prior antiangiogenic therapy.
Cometriq®cabozantinibCometriq® is a kinase inhibitor indicated for the treatment of patients with progressive, metastatic medullary thyroid cancer (MTC).
  • Brand
  • Generic
  • Investigational
Brand / Product Class Area of Study Phase Partnership
Cometriq® / cabozantinib / XL184multiple tyrosine kinase inhibitor (MET and RET)2nd line metastatic castrate-resistant prostate cancer (CRPC)IIIBristol-Myers Squibb
Cometriq® / cabozantinib / XL184multiple tyrosine kinase inhibitor (MET and RET)Medullary Thyroid cancer (MTC)IIIBristol-Myers Squibb
Cometriq® / cabozantinib (+ nivolumab) / XL184multiple tyrosine kinase inhibitor (MET and RET)Renal cell carcinoma (RCC)IIIBristol-Myers Squibb
Cometriq® / cabozantinib (+ nivolumab and ipilimumab) / XL184multiple tyrosine kinase inhibitor (MET and RET)Renal cell carcinoma (RCC)IIIBristol-Myers Squibb
foretinib / XL880multikinase inhibitor of c-Met & VEGFR-2.Gastric cancerIIGlaxoSmithKline
foretinib / XL880multikinase inhibitor of c-Met & VEGFR-2.Head & Neck cancerIIGlaxoSmithKline
foretinib / XL880multikinase inhibitor of c-Met & VEGFR-2.Papillary Renal cell carcinoma (RCC)IIGlaxoSmithKline
Cometriq® / cabozantinib / XL184immunotherapy1st line metastatic Breast cancerIIBristol-Myers Squibb
Cometriq® / cabozantinib / XL184multiple tyrosine kinase inhibitor (MET and RET)2nd line metastatic Glioblastoma Multiforme (GBM)IIBristol-Myers Squibb
Cometriq® / cabozantinib / XL184multiple tyrosine kinase inhibitor (MET and RET)2nd line metastatic Ovarian cancerIIBristol-Myers Squibb
Cometriq® / cabozantinib / XL184multiple tyrosine kinase inhibitor (MET and RET)Non Small Cell Lung Cancer (NSCLC)IIBristol-Myers Squibb
Cometriq® / cabozantinib / XL184immunotherapyRenal cell carcinoma (RCC)II
Cometriq® / cabozantinib / XL184multiple tyrosine kinase inhibitor (MET and RET)Various cancer typesIIBristol-Myers Squibb
XL281 (BMS-908662)Raf kinase inhibitor1st line metastatic Colorectal cancerIBristol-Myers Squibb
XL228multikinase inhibitorChronic Myelogenous Leukemia (CML)I
XL820KIT, PDGF and VEGF inhibitorGastrointestinal Stromal Tumors (GIST)I
XL765PI3K and mTOR inhibitorGlioblastoma Multiforme (GBM)ISanofi
XL888 (+ vemurafenib)Hsp90 inhibitorMelanomaI
XL019JAK inhibitorMyeloproliferative disordersI
XL147PI3K inhibitorNon Small Cell Lung Cancer (NSCLC)ISanofi
XL765PI3K and mTOR inhibitorNon Small Cell Lung Cancer (NSCLC)ISanofi
XL765PI3K and mTOR inhibitorVarious cancer typesISanofi
XL147PI3K inhibitorVarious cancer typesISanofi
XL281 (BMS-908662)Raf kinase inhibitorVarious cancer typesIBristol-Myers Squibb
XL844multiple tyrosine kinase inhibitor (CHK1 and CHK2)Various cancer typesI
XL820KIT, PDGF and VEGF inhibitorVarious cancer typesI
XL518MEK inhibitorVarious cancer typesIGenentech / Roche
XL228multikinase inhibitorVarious cancer typesI
XL413Cdc7 kinase inhibitorVarious cancer typesIBristol-Myers Squibb
XL139hedgehog pathway inhibitorVarious cancer typesIBristol-Myers Squibb
Cometriq® / cabozantinib / XL184multiple tyrosine kinase inhibitor (MET and RET)Multiple MyelomaIBristol-Myers Squibb
Cometriq® / cabozantinib (+ nivolumab) / XL184immunotherapyUrothelial cancerI
XL888Hsp90 inhibitorVarious cancer typesPreclinical

View additional information on product candidates here »

Source: http://www.exelixis.com

Recent News Headlines

Exelixis Announces Presentation of Cobimetinib Combination Therapy Data at the Society for Melanoma Research 2016 Congress That Support Genentech’s Planned Phase 3 Pivotal Trials

11/7/2016 12:56 pm

(Yahoo! Finance) Nov 7, 2016 - Encouraging data in BRAF wild type advanced melanoma presented in advance of initiation of phase 3 pivotal trial next year; the third pivotal phase 3 trial of cobimetinib announced this year, reflecting robust late-stage development program.

Exelixis and Pfizer Drugs Compete In Kidney Cancer Trial

10/10/2016 02:46 pm

(Reuters) Oct 10, 2016 - Exelixis's drug Cabometyx outperformed Pfizer's Sutent in a clinical study for the treatment of metastatic kidney cancer, suggesting it has the potential to become a first-line treatment, researchers said on Monday.

Exelixis Announces Phase 1 Trial Results for Cabozantinib in Combination with Nivolumab in Advanced Genitourinary Tumors

10/7/2016 03:59 pm

(Yahoo! Finance) Oct 7, 2016 - Exelixis, Inc. today announced results from a phase 1 trial of cabozantinib in combination with nivolumab in patients with previously treated genitourinary tumors.

Exelixis Announces Genentech Presentation of Preliminary Phase 1b Results for the Combination of Cobimetinib, Vemurafenib and Atezolizumab at ESMO 2016 Congress

10/7/2016 03:58 pm

(Yahoo! Finance) Oct 7, 2016 - Exelixis, Inc. today announced that its collaborator Genentech, a member of the Roche Group, will present preliminary results from a phase 1b clinical trial evaluating the safety and clinical activity of the triple combination of cobimetinib, vemurafenib, and atezolizumab in patients with previously untreated BRAF V600 mutation-positive advanced melanoma.

Exelixis Provides Update on Timing of Key Cabozantinib Clinical Data Presentation at the ESMO 2016 Congress

9/21/2016 04:51 pm

(Exelixis) Sept 20, 2016 - CABOSUN results now subject of an oral presentation in Presidential Symposium 3 on Monday, October 10.

EU Nod For Exelixis’ Kidney Cancer Drug

9/14/2016 04:39 pm

(PharmaTimes [UK]) Sept 14, 2016 - European regulators have approved a new second-line treatment option for patients with advanced kidney cancer.

Adam Feuerstein's Biotech Stock Mailbag: Heron, Exelixis

7/12/2016 03:21 pm

(TheStreet) July 8, 2016 - TheStreet's Adam Feuerstein answers reader questions about biotech stocks.

Exelixis Announces Genentech Presentation of Preliminary Phase 1B Trial Results for the Combination of Cobimetinib and Atezolizumab at ASCO 2016 Annual Meeting

6/5/2016 11:19 pm

(Yahoo! Finance) June 5, 2016 - Exelixis, Inc. today announced that its collaborator Genentech, a member of the Roche Group, will present preliminary results from a phase 1b clinical trial evaluating the safety and clinical activity of cobimetinib, an Exelixis-discovered MEK inhibitor, in combination with atezolizumab, an anti-PD-L1 antibody discovered and developed by Genentech, in patients with metastatic colorectal cancer (CRC).

Exelixis and Its Partner Ipsen Announce Phase 3 Trial Results of CABOMETYX™ (cabozantinib) Tablets Demonstrating Significant Overall Survival Benefit For Previously Treated Patients With Advanced Renal Cell Carcinoma Presented at ASCO

6/5/2016 11:09 pm

(TheStreet.com) June 5, 2016 - Exelixis, Inc. and Ipsen today announced overall survival (OS) results from the phase 3 METEOR trial of CABOMETYX™ (cabozantinib) tablets in patients with advanced renal cell carcinoma (RCC) who have received prior anti-angiogenic therapy.

Durvalumab Monotherapy Demonstrates Efficacy In Urothelial Bladder Cancer

6/5/2016 06:02 pm

(pharmiweb.com) June 5, 2016 - Data show objective response rate (ORR) of 31% in all evaluable patients and 46% in patients with PD-L1-high-expressing tumors.

Juno Therapeutics’ Defined Composition CD19 Product Candidates Demonstrate Encouraging Clinical Outcomes and Tolerability

6/4/2016 05:03 pm

(Juno) June 4, 2016 - Durable remissions in adult ALL, NHL, and CLL patients with JCAR014; 100% complete molecular remission as measured by flow cytometry in pediatric ALL patients with JCAR017 and fludarabine/cyclophosphamide.

Adding Intraperitoneal Chemotherapy Slows Ovarian Cancer Progression

6/3/2016 02:00 pm

(ASCO Annual Meeting) June 3, 2016 - For some women with advanced ovarian cancer that was successfully treated surgically, delivering chemotherapy into the abdomen (intraperitoneal, or IP) as well as intravenously (IV) appears more effective than IV chemotherapy alone.

Chemotherapy Combination With Capecitabine Extends Survival After Pancreatic Cancer Surgery

6/3/2016 02:00 pm

(ASCO Annual Meeting) June 3, 2016 - A European phase III trial, one of the largest ever conducted in pancreatic cancer, showed that adding the oral drug capecitabine chemotherapy to gemcitabine prolongs survival without increased toxicity.

Exelixis Announces Results from Randomized Phase 2 Trial CABOSUN Demonstrate Cabozantinib Significantly Improved Progression-Free Survival versus Sunitinib in Previously Untreated Advanced Renal Cell Carcinoma

5/23/2016 05:57 pm

(4-traders) May 23, 2016 - Exelixis, Inc. today announced positive top-line results from the CABOSUN randomized phase 2 trial of cabozantinib in patients with previously untreated advanced renal cell carcinoma (RCC).

Myriad Genetics' Statement on HIPAA Complaint from Four Patients

5/20/2016 11:04 am

(Myriad) May 19, 2016 - Myriad Genetics, Inc., a leader in molecular diagnostics and personalized medicine, today announced a complaint was filed against the Company with the Department of Health and Human Services on behalf of four individuals seeking their genetic testing results.

Promise of Nearly a Year of Life on Targeted Drug Not Reality for All Liver Cancer Patients, Study Finds

5/17/2016 11:05 am

(UNC Lineberger) May 16, 2016 - Study led by UNC Lineberger Comprehensive Cancer Center members Hanna Sanoff and Stacie Dusetzina found that the liver cancer drug can have serious side effects and significant out-of-pocket costs for advanced liver cancer patients.

Exelixis Announces FDA Approval of CABOMETYX™ (Cabozantinib) Tablets for Patients with Advanced Renal Cell Carcinoma Who Have Received Prior Anti-Angiogenic Therapy

4/25/2016 07:35 pm

(Exelixis) Apr 25, 2016 - CABOMETYX is the first therapy to demonstrate improved overall survival, progression-free survival and objective response rate in a large, randomized phase 3 trial of patients with advanced kidney cancer.

FDA Outlines Standards for Anti-Abuse Generic Painkillers

3/24/2016 11:05 am

(Washington Post/Associated Press) Mar 24, 2016 - Federal officials are encouraging generic drugmakers to reformulate their painkillers to make them harder to abuse, the latest in a string of steps designed to combat abuse of highly-addictive pain drugs like codeine and oxycodone.

On Comeback Trail, Exelixis Reels In $200M Deal For Cancer Drug

3/1/2016 05:46 pm

(Xconomy San Francisco) Feb 29, 2016 — Cancer drug developer Exelixis continued its comeback, announcing Monday a deal with Ipsen that will pay the South San Francisco, CA-based biotech $200 million upfront.

Mylan Strikes $7.2 Billion Deal for Meda as Earnings Miss

2/11/2016 12:01 pm

(Bloomberg) Feb 10, 2016 - Mylan’s pursuit of Meda has been a lengthy one, and comes as the generic drug industry has been consolidating with deals by Mylan, Allergan Plc, Teva Pharmaceutical Industries Ltd. and others.

Exelixis Kidney Cancer Survival Benefit Doesn't Address Competitive Question

2/1/2016 05:24 pm

(TheStreet) Feb 1, 2016 - Exelixis didn't provide specifics about the duration of Cometriq's survival benefit, so it's not known if the new data will help the company compete any better against Bristol-Myers Squibb.

Exelixis Announces European Medicines Agency Acceptance of Marketing Authorization Application for Cabozantinib as a Treatment for Advanced Renal Cell Carcinoma

1/29/2016 06:03 pm

(TheStreet) Jan 28, 2016 - Exelixis, Inc. today announced the European Medicines Agency (EMA) has accepted for review the Marketing Authorization Application (MAA) for cabozantinib as a treatment for patients with advanced renal cell carcinoma (RCC) who have received one prior therapy.

Exelixis Announces U.S. FDA Deems New Drug Application Sufficiently Complete and Grants Priority Review for Cabozantinib as a Treatment for Advanced Renal Cell Carcinoma

1/28/2016 05:43 pm

(Yahoo! Finance) Jan 28, 2016 - Exelixis, Inc. today announced that the U.S. Food & Drug Administration (FDA) has determined the company's New Drug Application (NDA) for cabozantinib as a treatment for patients with advanced renal cell carcinoma (RCC) who have received one prior therapy to be sufficiently complete to permit a substantive review.

Multi-Center Study Reveals Unique Subtypes of Most Common Malignant Brain Cancer

1/28/2016 11:04 am

(MD Anderson) Jan 28, 2016 - An international collaborative study has revealed detailed new information about diffuse glioma, the most common type of tumor found in some 80 percent of adult brain cancer patients, raising hopes that better understanding of these disease groups may aid improved clinical outcomes.

Chemotherapy May Benefit Subgroup of Stage-2 Colon Cancer Patients

1/21/2016 11:04 am

(Stanford Medicine) Jan 20, 2016 - Some stage-2 colon cancer patients may benefit from the use of chemotherapy after surgery, according to a retrospective study by researchers at the Stanford University School of Medicine.

Exelixis Submits Marketing Authorization Application in the European Union for Cabozantinib as a Treatment for Advanced Renal Cell Carcinoma

1/11/2016 05:10 pm

(Morningstar) Jan 11, 2016 - Exelixis, Inc. today announced that it has submitted a Marketing Authorization Application (MAA) for cabozantinib as a treatment for patients with advanced renal cell carcinoma (RCC) who have received one prior therapy to the European Medicines Agency (EMA).

Exelixis Completes Submission of New Drug Application for Cabozantinib for the Treatment of Advanced Renal Cell Carcinoma

12/23/2015 04:38 pm

(Yahoo! Finance) Dec 23, 2015 - Exelixis, Inc. today announced that it has completed the submission of its rolling New Drug Application (NDA) with the U.S. Food and Drug Administration (FDA) for cabozantinib as a treatment for patients with advanced renal cell carcinoma (RCC) who have received one prior therapy.

Exelixis Announces European Commission Approval of COTELLIC™ (Cobimetinib) for Use in Combination with Vemurafenib in Advanced BRAF V600 Mutation-Positive Melanoma

11/25/2015 03:29 pm

(Morningstar) Nov 25, 2015 - COTELLIC’s third regulatory approval, following Switzerland (August 2015) and the United States (November 2015).

Exelixis Announces Presentation of Positive Overall Survival Results for COTELLIC™ in Combination with Vemurafenib in Advanced BRAF V600 Mutation-Positive Melanoma at Society for Melanoma Research 2015 International Congress

11/23/2015 12:51 pm

(Exelixis) Nov 21, 2015 - Exelixis, Inc. today announced the presentation of positive overall survival (OS) results from coBRIM, the phase 3 pivotal trial evaluating COTELLIC™ (cobimetinib) in patients with previously untreated resectable, locally advanced or metastatic melanoma carrying a BRAF V600E or V600K mutation, in combination with vemurafenib.

Exelixis Initiates Rolling Submission of U.S. New Drug Application for Cabozantinib for the Treatment of Advanced Kidney Cancer

10/22/2015 04:50 pm

(StreetInsider) Oct 22, 2015 - Exelixis, Inc. today announced the company has initiated submission of its rolling New Drug Application (NDA) to the U.S. Food & Drug Administration (FDA) for cabozantinib for the treatment of advanced renal cell carcinoma (RCC) patients who have received one prior therapy.

Exelixis Announces Positive Overall Survival Results from Phase 3 Pivotal Trial of Cobimetinib in Combination with Vemurafenib in Patients with BRAF V600 Mutation-Positive Advanced Melanoma

10/6/2015 11:57 am

(MarketWatch) Oct 6, 2015 - Exelixis, Inc. today announced positive overall survival (OS) results from coBRIM, the phase 3 pivotal trial evaluating cobimetinib, a specific MEK inhibitor discovered by Exelixis, in combination with vemurafenib in previously untreated patients with unresectable locally advanced or metastatic melanoma carrying a BRAF V600 mutation.

Exelixis Announces Positive Results from METEOR Phase 3 Pivotal Trial of Cabozantinib in Advanced Renal Cell Carcinoma Presented at European Cancer Congress 2015

9/28/2015 06:46 pm

(StreetInsider) Sept 25, 2015 - Exelixis, Inc. today announced positive results from METEOR, the phase 3 pivotal trial comparing cabozantinib to everolimus in 658 patients with renal cell carcinoma (RCC) who have experienced disease progression following treatment with a VEGF receptor tyrosine kinase inhibitor (TKI).

Exelixis Hires Three Veeps As Market Plans Loom For Two Drugs

9/25/2015 05:00 pm

(Xconomy San Francisco) Sept 24, 2015 - San Francisco Bay Area biotech firm Exelixis is bringing on board three new executives in anticipation of two drugs gaining FDA approval.

Exelixis Announces First Regulatory Approval of Cobimetinib in Switzerland

8/27/2015 11:58 am

(MarketWatch) Aug 27, 2015 - Exelixis, Inc. today announced that Swissmedic, the Swiss licensing and supervisory authority of Switzerland, has approved cobimetinib for use in combination with vemurafenib as a treatment for patients with advanced melanoma.

FDA Grants Breakthrough Therapy Designation to Exelixis’ Cabozantinib for the Treatment of Renal Cell Carcinoma in Patients Who Received One Prior Therapy

8/24/2015 04:14 pm

(Yahoo! Finance) Aug 24, 2015 - Exelixis, Inc. today announced the U.S. Food & Drug Administration (FDA) has granted Breakthrough Therapy Designation to cabozantinib, Exelixis’ lead compound, as a potential treatment for patients with advanced renal cell carcinoma (RCC) who have received one prior therapy.

Rising Cancer Costs Pit Doctors Against Drugmakers

7/24/2015 11:02 am

(CBS Moneywatch) July 24, 2015 - Spending on cancer drugs is skyrocketing and shows no signs of slowing.

Focusing on Only 1% of Spending Will Not Solve Nation's Health Care Challenges

7/24/2015 11:02 am

(PhRMA/The Catalyst blog) July 23, 2015 - The article ignores the fact that cancer medicines represent only one-fifth of total spending on cancer treatment.

30-year Study Shows That Moderate Hormone Suppression May Be Enough In Thyroid Cancer

7/20/2015 11:03 am

(UCCC/Colorado Cancer Blogs) July 16, 2015 - A study of long-term thyroid cancer outcomes shows that moderate suppression of thyroid-stimulating hormone (TSH), which drives the disease, may be as beneficial as more extreme hormone suppression.

July 2015 Decisions News Release

7/14/2015 11:04 am

(Scottish Medicines Consortium) July 13, 2015 - The Committee was unable to recommend two other medicines considered under the PACE process, olaparib (Lynparza) for ovarian cancer and vinflunine (Javlor) for cancer of the bladder and the urinary tract.

House Passes Bill to Improve Safety Monitoring of Medical Devices

7/13/2015 11:04 am

(Wall Street Journal) July 12, 2015 - A sweeping medical research bill that passed the House on Friday included a provision aimed at improving safety monitoring of medical devices—an amendment inspired by a controversial gynecological device.

Next Round of Grant Solicitations for Provocative Questions Announced

7/13/2015 11:04 am

(NCI/Cancer Currents blog) July 10, 2015 - NCI recently issued a new solicitation for research proposals under the Provocative Questions (PQ) Initiative, a program aimed at promoting cancer-related research on important yet understudied areas or research questions that have proven difficult to address.

More Men With Prostate Cancer Are Opting For Surveillance

7/8/2015 11:03 am

(Reuters Health) July 7, 2015 - Men with early-stage prostate cancer are increasingly opting for regular monitoring and holding off on treatment unless the disease progresses, a new study suggests.

Astellas Announces New Data in Advanced Prostate and Breast Cancers, Acute Myeloid Leukemia, and Lung and Renal Cancers to be Presented at 2015 ASCO Annual Meeting

5/15/2015 12:01 pm

(Benzinga) May 14, 2015 - Astellas today announced several abstracts across multiple cancers that will be presented at the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting on May 29-June 2 in Chicago.

Rosetta Genomics Launches Two Assays for Bladder Cancer

5/14/2015 01:05 pm

(MarketWatch) May 14, 2015 - Rosetta Genomics Ltd., a leading developer and provider of microRNA-based molecular and other diagnostics, announces that the Company will commercially introduce two FGFR3 gene mutation assays; one for diagnostic monitoring using urine samples to detect recurrences of FGFR3-positive low-grade bladder cancers, and the other in conjunction with Ki67 expression for tissue-based prognostication at initial diagnosis of bladder cancer.

Takeda Dumps Late-Stage Lymphoma Drug on Trial Failure

5/14/2015 01:05 pm

(PharmaTimes [UK]) May 13, 2015 - Takeda has killed off a late stage programme assessing the potential of alisertib in lymphoma after interim analysis failed to show any benefit in progression-free survival.

Babies Who Eat Solid Food Earlier Are Less Prone To Paediatric Cancer, Study Reveals

5/1/2015 12:01 pm

(IBTimes [Australia Edition]) May 1, 2015 - The latest research might help eliminate confusion regarding when mothers start feeding solid food to their babies.

New Antibody-Drug Conjugate Shows Early Promise for Patients With Metastatic HER2-positive Breast Cancer

4/20/2015 11:01 am

(AACR) Apr 20, 2015 - An investigational antibody-drug conjugate called MM-302 was safe, tolerable, and showed signs of clinical activity in heavily pretreated patients with metastatic, HER2-positive breast cancer, according to data from a phase I clinical trial presented here at the AACR Annual Meeting 2015, April 18-22.

Investigational ER Degrader Safe, With Early Signs of Antitumor Activity Against Advanced ER-positive Breast Cancer

4/20/2015 11:01 am

(AACR) Apr 20, 2015 - The new investigational estrogen receptor (ER) degrader GDC-0810 was safe and tolerable in postmenopausal women with advanced ER-positive breast cancer, and a subset of the women, all of whom were previously treated with standard endocrine therapy, gained clinical benefit from the drug, according to data from a first-in-human phase I/IIa clinical trial presented here at the AACR Annual Meeting 2015, April 18-22.

ELCC 2015 Press Release: DNA Blood Test Detects Lung Cancer Mutations

4/17/2015 11:05 am

(ESMO) Apr 17, 2015 - Cancer DNA circulating in the bloodstream of lung cancer patients can provide doctors with vital mutation information that can help optimise treatment when tumour tissue is not available, an international group of researchers has reported at the European Lung Cancer Conference (ELCC) in Geneva, Switzerland.

FDA: Don’t Use Treanda Injection (Solution) With Certain CSTDs

3/26/2015 12:03 pm

(ACCC) Mar 25, 2015 - The U.S. Food and Drug Administration (FDA) is warning healthcare professionals not to use Treanda Injection (45 mg/0.5 mL or 180 mg/2 mL solution) with closed system transfer devices (CSTD), adapters, and syringes containing polycarbonate or acrylonitrile-butadiene-styrene (ABS).